The nonstaff members of IAS–USA Drug Resistance Mutations Group are volunteers and are not compensated for their role in overseeing the program. Listed below are the IAS–USA Drug Resistance Mutations Group members and their financial relationships with ineligible companies within the past 12 months from the date of disclosure as of September 23, 2022.
Members
Vincent Calvez, MD, PhD
Pierre et Marie Curie University
Pitié-Salpêtrière Hospital
Paris, France
Dr Calvez has served as an advisor or consultant to and has received research grants from Bristol-Myers Squibb, Johnson & Johnson, Merck Sharp & Dohme, Inc, ViiV Healthcare, and Gilead Sciences, Inc.
Francesca Ceccherini-Silberstein, PhD
University of Rome Tor Vergata
Rome, Italy
Dr Ceccherini-Silberstein has been a consultant to ViiV Healthcare, Gilead Sciences, Inc, and Merck Sharp & Dohme, Inc, and has received research grants from ViiV Healthcare, Gilead Sciences, Inc, and Merck Sharp & Dohme, Inc.
Charlotte Charpentier, PharmD
Paris Diderot University
Bichat-Claude Bernard Hospital
Paris, France
Dr Charpentier serves as an advisor for ViiV Healthcare, Gilead Sciences, Inc, Janssen Therapeutics, Theratechnologies, and Merck Sharp & Dohme, Inc, and has received research grants from ViiV Healthcare.
Huldrych F. Günthard, MD
Professor of Infectious Diseases
University Hospital Zurich
Institute of Medical Virology
Zurich, Switzerland
Dr Günthard has served as a consul-tant to Merck & Co, Inc, ViiV Healthcare, GlaxoSmithKline, Novartis, Johnson and Johnson Inc, and Gilead Sciences, Inc, and has received research grants from Gilead Sciences, Inc.
Roger Paredes, MD, PhD
HIV Unit and IrsiCaixa AIDS Research Institute
Hospital Universitari Germans Trias I Pujol
Badalona, Spain
Dr Paredes has received research grants from ViiV Healthcare and Merck Sharp & Dohme, Inc and has been a consultant for Gilead Sciences, Inc, ViiV Healthcare, Pfizer, Inc, Theratechnologies, Inc, and Eli Lilly and Company.
Douglas D. Richman, MD (Group Vice Chair)
Professor of Pathology and Medicine
University of California San Diego
San Diego, California
Dr Richman has been a consultant to Antiva Biosciences and Merck & Co, Inc, and serves as Chair of the Data Man-agement Committee of Gilead Sciences, Inc.
Robert W. Shafer, MD
Assistant Professor
Stanford University
Stanford, California
Dr Shafer has received research grants from Janssen Therapeutics, Vela Diagnostics, and InSilixa, Inc, and personal consult-ing fees from Abbott Diagnostics.
Annemarie M. Wensing, MD, PhD (Group Chair)
University Medical Center Utrecht
Utrecht, The Netherlands
University of the Witwatersrand
Johannesburg, South Africa
Dr Wensing has served on advisory boards for ViiV Healthcare, GlaxoSmithKline, Janssen Therapeutics, and Gilead Sciences, Inc, and has received investigator initiated research grants from Gilead Sciences, Inc. Ms Jacobsen has no relevant financial relationships with ineligible companies to disclose. All relevant financial relationships with ineligible companies have been mitigated.